Octavio Espinoza sold $2.8M of LGND
Chief Financial Officer at LIGAND PHARMACEUTICALS INC. 13,423 shares at an average of $205.83, traded Mar 4, 2026, filed Mar 6, 2026.
Score components
- +22RoleCFO
- +25Trade size$2.8M at market
- +10Share of holdings soldSold 38% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002001011-26-000023, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 4, 2026 | MOption exercise Common Stock10b5-1 | +1,607 | $58.49 | $94k | 34,619 | Mar 6, 2026 |
| Mar 4, 2026 | MOption exercise Common Stock10b5-1 | +466 | $80.72 | $38k | 35,085 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -699 | $198.71 | $139k | 34,386 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -53 | $200.08 | $11k | 34,333 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -698 | $201.09 | $140k | 33,635 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -950 | $201.73 | $192k | 32,685 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -697 | $202.79 | $141k | 31,988 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -668 | $203.63 | $136k | 31,320 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -743 | $204.74 | $152k | 30,577 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -1,457 | $205.79 | $300k | 29,120 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -1,588 | $206.89 | $329k | 27,532 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -2,457 | $207.91 | $511k | 25,075 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -3,413 | $208.80 | $713k | 21,662 | Mar 6, 2026 |
| Mar 4, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -1,607 | $0.00 | $0 | 0 | Mar 6, 2026 |
| Mar 4, 2026 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -466 | $0.00 | $0 | 0 | Mar 6, 2026 |
Related signals
Other insiders at LIGAND PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 10Weak | LIGAND PHARMACEUTICALS INC | Andrew Reardon CLO & Secretary | $1.5M 5,000 shares | -14% | |
| 43Moderate | LIGAND PHARMACEUTICALS INC | Martine Zimmermann director | $342k 1,200 shares | -24% | |
| 33Weak | LIGAND PHARMACEUTICALS INC | Andrew Reardon CLO & Secretary | $1.4M 5,000 shares | -12% | |
| 40Moderate | LGNDsell LIGAND PHARMACEUTICALS INC | Jason Aryeh director | $1.3M 5,000 shares | -5% | |
| 32Weak | LIGAND PHARMACEUTICALS INC | John L Lamattina director | $434k 2,161 shares | -7% | |
| 35Weak | LIGAND PHARMACEUTICALS INC | Stephen L Sabba director | $208k 1,000 shares | -3% | |
| 28Weak | LIGAND PHARMACEUTICALS INC | Octavio Espinoza Chief Financial Officer | $688k 3,057 shares | -13% | |
| 25Weak | LIGAND PHARMACEUTICALS INC | Andrew Reardon CLO & Secretary | $1.0M 5,000 shares | -12% | |
| 31Weak | LIGAND PHARMACEUTICALS INC | Stephen L Sabba director | $410k 2,034 shares | -6% | |
| 20Weak | LIGAND PHARMACEUTICALS INC | John W Kozarich director | $94k 467 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.